Product image of Novain (Oxybuprocaine Hydrochloride) supplied by GNH India

Novain

Active Ingredient:
Oxybuprocaine Hydrochloride
Origin:
EU

Novain (Oxybuprocaine Hydrochloride)

Oxybuprocaine Hydrochloride, the active ingredient in Novain, is a local anesthetic (ester type) presented as a sterile ophthalmic solution for ocular use. It provides topical anesthesia for diagnostic eye examinations, minor surgical procedures, and relief of corneal irritation in patients of all ages.
GNH India supplies Novain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Agepha Pharma S.R.O

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Novain is a topical ophthalmic anesthetic used to temporarily block sensory nerve transmission in the eye.

  • Diagnostic eye examinations: provides rapid, reversible anesthesia for corneal sensitivity testing and slit‑lamp evaluation.
  • Minor ocular surgeries: facilitates procedures such as cataract extraction, laser photocoagulation, and intraocular lens implantation.
  • Corneal abrasion or foreign body removal: relieves pain and discomfort during mechanical debridement or extraction.

How It Works

  • Oxybuprocaine Hydrochloride reversibly blocks voltage‑gated sodium channels on peripheral nerve membranes in the cornea and conjunctiva. By inhibiting sodium influx, it prevents the initiation and propagation of action potentials, resulting in temporary loss of sensation without affecting the underlying tissue integrity.

Side Effects

Novain may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects

  • Stinging or burning sensation upon instillation.
  • Transient blurred vision lasting a few minutes.
  • Conjunctival hyperemia (redness).
  • Mild tearing or lacrimation.
  • Temporary increase in intra‑ocular pressure (rare).

Serious or Rare Side Effects

  • Allergic contact dermatitis or severe hypersensitivity reaction.
  • Corneal epithelial toxicity leading to ulceration.
  • Persistent corneal edema.
  • Systemic toxicity (e.g., CNS depression) with excessive dosing.
  • Vision loss if used improperly or in high concentrations.

Precautions & Warnings

Novain should be used under professional supervision with attention to patient history and ocular condition.

  • Allergy assessment: confirm no known hypersensitivity to oxybuprocaine or related ester anesthetics.
  • Limited duration: avoid prolonged or repeated applications beyond recommended intervals.
  • Corneal health: do not use on compromised corneal epithelium without specialist advice.
  • Contact lens wear: advise removal of lenses before administration.
  • Pediatric use: exercise caution and follow specialist guidance.
  • Store at room temperature: keep in original container, protect from moisture and direct light.

Avoid Interactions

Novain may interact with other ocular or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid)

  • Concurrent use of multiple topical ocular anesthetics: risk of cumulative neurotoxicity.
  • Systemic central nervous system depressants (e.g., barbiturates): potential additive sedation if systemic absorption occurs.

Moderate Interactions (Monitor Closely)

  • Anticholinergic eye drops (e.g., atropine): may alter pupil response.
  • Beta‑blocker ophthalmic solutions: possible reduction in intra‑ocular pressure control.
  • Topical antibiotics: increased risk of local irritation.
  • Contact lens wear: may enhance drug absorption and irritation.

Frequently Asked Questions

Novain is a prescription ophthalmic solution containing oxybuprocaine hydrochloride. It is used to provide short‑acting topical anesthesia for diagnostic eye examinations, to facilitate minor ocular surgical procedures, and to relieve pain during corneal abrasion or foreign‑body removal.

Oxybuprocaine hydrochloride blocks voltage‑gated sodium channels on peripheral nerve endings in the cornea and conjunctiva. This inhibition prevents the initiation and spread of nerve impulses, resulting in temporary loss of sensation without affecting the structural integrity of ocular tissues.

The appropriate dose of Novain is determined by the prescribing clinician based on the specific procedure, patient age, and ocular condition. The prescriber will specify the number of drops, concentration, and timing required for safe and effective anesthesia.

Safety data for oxybuprocaine hydrochloride in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Novain, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Novain (oxy­buprocaine) is an ester‑type local anesthetic offering rapid onset and short duration of action, similar to proparacaine. Compared with amide‑type agents such as lidocaine, oxybuprocaine has a quicker metabolism by plasma esterases, reducing the risk of systemic accumulation but may cause more frequent ocular irritation.

Novain should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations to maintain sterility and potency.

Novain is applied topically to the eye as a sterile drop. The prescriber determines the number of drops and the interval before the procedure. Administration should be performed by trained personnel using aseptic technique to avoid contamination.

Serious risks include severe allergic reactions, corneal epithelial toxicity leading to ulceration, and rare systemic toxicity such as central nervous system depression if excessive amounts are absorbed. Immediate medical attention is required if any signs of serious adverse effects appear.

Novain should not be used in patients with known hypersensitivity to oxybuprocaine, other ester‑type anesthetics, or any component of the formulation. It is also contraindicated on severely damaged corneal epithelium or in eyes with active infection unless directed by an ophthalmologist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.